ABVX.PAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:35):

Stats
本日の出来高	13 478.00
平均出来高	30 185.00
時価総額	932.44M
EPS	€0 ( 2024-04-07 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.32
ATR14	€0.0470 (0.32%)

ボリューム相関

長: -0.05 (neutral)

短: 0.77 (moderate)

Signal:(59.777) Neutral

Abivax SA 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Abivax SA 相関 - 通貨/商品

-0.16
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.01
( neutral )

0.09
( neutral )

-0.16
( neutral )

Abivax SA 財務諸表

Annual	2023
収益:	€4.62M
総利益:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2023
収益:	€4.62M
総利益:	€3.91M (84.70 %)
EPS:	€-3.43

FY	2022
収益:	€0
総利益:	€-71 000.00 (0.00 %)
EPS:	€-3.13

FY	2021
収益:	€37 000.00
総利益:	€37 000.00 (100.00 %)
EPS:	€-3.39

Financial Reports:

No articles found.

Abivax SA

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.